Over 2 years, the risk of the primary outcome of combined cardiovascular death, myocardial infarction, and stroke, was significantly lower with P2Y12 inhibitor monotherapy compared with aspirin (HR 0.88; 95% CI 0.79–0.97; p = 0.012), mainly owing to less myocardial infarction (HR 0.77; 95% CI 0.66–0.90; p < 0.001) [21]. Here, P2RY12 is linked to myocardial infarction.